An internal Armour memo suggested it was "vitally important" that Armour sell the products manufactured from plasma collected prior to the March 1983 FDA memorandum as quickly as possible.
Linked evidence
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Regulation of Commercial Factor Concentrates
Key Person(s)
Chris R Bishop